Marksans Pharma, 524404, MARKSANS Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

3,202.06
14.96
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

2,894.08
0.35%
1.89

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

13.02
10.31
9.54

EBITDA CAGR (%)

10 Years
5 Years
3 Years

14.07
26.99
6.13

PAT CAGR (%)

10 Years
5 Years
3 Years

14.93
41.15
16.40

P:E (Median)

8 Years
5 Years
3 Years

15.67
11.86
11.57

P:BV (Average)

8 Years
5 Years
3 Years

3.38
2.22
2.45

EV:EBITDA (Average)

8 Years
5 Years
3 Years

13.29
8.23
7.26

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Dec 22 Dec 21 Var% Sep 22 Sep 21 Var% Jun 22 Jun 21 Var% Mar 22 Mar 21 Var%
Net Sales 172.75 165.94 4.10% 170.26 168.85 0.84% 159.15 147.22 8.10% 176.28 137.58 28.13%
Expenses 148.93 138.12 7.83% 136.49 134.92 1.16% 147.55 122.12 20.82% 149.41 110.80 34.85%
EBITDA 23.82 27.82 -14.38% 33.77 33.93 -0.47% 11.61 25.10 -53.75% 26.87 26.78 0.34%
EBIDTM 13.79% 16.77% 19.84% 20.09% 7.29% 17.05% 15.24% 19.46%
Other Income 15.71 12.07 30.16% 21.03 8.60 144.53% 19.43 13.94 39.38% 7.65 11.91 -35.77%
Interest 0.85 0.69 23.19% 1.29 1.20 7.50% 0.82 0.63 30.16% 1.28 2.14 -40.19%
Depreciation 4.18 4.52 -7.52% 4.53 4.30 5.35% 4.52 4.23 6.86% 4.61 4.15 11.08%
PBT 34.50 34.68 -0.52% 48.98 37.02 32.31% 25.70 34.18 -24.81% 28.63 32.40 -11.64%
Tax 8.88 8.62 3.02% 8.75 9.42 -7.11% 6.50 5.27 23.34% 7.20 8.72 -17.43%
PAT 25.62 26.06 -1.69% 40.23 27.60 45.76% 19.21 28.91 -33.55% 21.43 23.69 -9.54%
PATM 14.83% 15.70% 23.63% 16.34% 12.07% 19.63% 12.16% 17.22%
EPS 0.64 0.65 -1.54% 1.00 0.68 47.06% 0.48 0.72 -33.33% 0.53 0.59 -10.17%

Description Dec 22 Dec 21 Var% Sep 22 Sep 21 Var% Jun 22 Jun 21 Var% Mar 22 Mar 21 Var%
Net Sales 479.83 362.63 32.32% 452.56 361.20 25.29% 433.77 348.96 24.30% 418.04 330.20 26.60%
Expenses 403.19 304.83 32.27% 372.30 301.10 23.65% 360.91 271.63 32.87% 354.40 234.82 50.92%
EBITDA 76.64 57.80 32.60% 80.27 60.10 33.56% 72.86 77.34 -5.79% 63.64 95.37 -33.27%
EBIDTM 15.97% 15.94% 17.74% 16.64% 16.80% 22.16% 15.22% 28.88%
Other Income 17.65 12.06 46.35% 14.15 8.57 65.11% 16.50 5.88 180.61% 15.34 6.01 155.24%
Interest 2.35 0.95 147.37% 2.54 1.50 69.33% 1.80 0.97 85.57% 5.03 2.83 77.74%
Depreciation 12.74 8.56 48.83% 14.05 7.39 90.12% 11.12 7.47 48.86% 21.36 1.33 1,506.02%
PBT 79.20 60.35 31.23% 77.83 59.78 30.19% 76.45 74.78 2.23% 52.60 97.22 -45.90%
Tax 16.90 12.08 39.90% 17.71 13.49 31.28% 16.26 12.18 33.50% 22.95 17.73 29.44%
PAT 62.31 48.27 29.09% 60.12 46.29 29.88% 60.18 62.60 -3.87% 29.65 79.50 -62.70%
PATM 12.98% 13.31% 13.28% 12.81% 13.87% 17.94% 7.09% 24.08%
EPS 1.57 1.20 30.83% 1.52 1.13 34.51% 1.46 1.51 -3.31% 0.72 1.94 -62.89%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Net Sales 678.44 658.29 599.55 433.42 424.16 294.66 215.84 358.13 405.59 314.94 192.30 Net Sales Growth 9.50% 9.80% 38.33% 2.18% 43.95% 36.52% -39.73% -11.70% 28.78% 63.78% Cost Of Goods Sold 398.04 377.59 337.91 245.41 236.34 169.35 112.37 178.18 218.16 169.63 102.70 Gross Profit 280.40 280.70 261.63 188.00 187.82 125.31 103.47 179.95 187.44 145.31 89.59 GP Margin 41.33% 42.64% 43.64% 43.38% 44.28% 42.53% 47.94% 50.25% 46.21% 46.14% 46.59% Total Expenditure 582.38 544.57 485.84 361.93 360.83 265.52 202.15 258.76 299.58 236.23 151.47 Power & Fuel Cost - 11.49 10.90 8.95 8.44 7.26 7.21 7.55 7.74 6.46 4.57 % Of Sales - 1.75% 1.82% 2.06% 1.99% 2.46% 3.34% 2.11% 1.91% 2.05% 2.38% Employee Cost - 60.46 54.64 48.51 46.33 45.86 39.77 26.13 23.65 21.39 15.39 % Of Sales - 9.18% 9.11% 11.19% 10.92% 15.56% 18.43% 7.30% 5.83% 6.79% 8.00% Manufacturing Exp. - 73.81 56.39 32.15 12.69 11.52 11.99 13.99 15.42 13.33 3.83 % Of Sales - 11.21% 9.41% 7.42% 2.99% 3.91% 5.56% 3.91% 3.80% 4.23% 1.99% General & Admin Exp. - 16.91 14.79 16.19 22.68 10.95 10.61 9.42 7.50 7.95 13.87 % Of Sales - 2.57% 2.47% 3.74% 5.35% 3.72% 4.92% 2.63% 1.85% 2.52% 7.21% Selling & Distn. Exp. - 1.78 8.56 10.37 34.30 20.58 20.20 23.48 21.52 17.46 11.09 % Of Sales - 0.27% 1.43% 2.39% 8.09% 6.98% 9.36% 6.56% 5.31% 5.54% 5.77% Miscellaneous Exp. - 2.54 2.64 0.34 0.04 0.00 0.00 0.00 5.59 0.00 11.09 % Of Sales - 0.39% 0.44% 0.08% 0.01% 0% 0% 0% 1.38% 0% 0.01% EBITDA 96.07 113.72 113.71 71.49 63.33 29.14 13.69 99.37 106.01 78.71 40.83 EBITDA Margin 14.16% 17.28% 18.97% 16.49% 14.93% 9.89% 6.34% 27.75% 26.14% 24.99% 21.23% Other Income 63.82 42.25 31.16 0.17 7.93 7.43 17.75 13.21 12.82 8.41 7.61 Interest 4.24 3.80 5.34 7.29 6.56 7.67 4.49 6.20 13.11 15.21 10.13 Depreciation 17.84 17.66 15.19 11.64 8.69 12.25 15.00 14.75 9.03 8.66 8.70 PBT 137.81 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 63.26 29.61 Tax 31.33 30.52 25.95 14.82 12.39 4.23 0.40 20.14 29.58 7.70 -9.98 Tax Rate 22.73% 22.69% 20.87% 28.11% 22.12% 25.41% 3.35% 21.98% 30.59% 12.17% -33.70% PAT 106.49 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 55.56 39.58 PAT before Minority Interest 106.49 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 55.56 39.58 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 15.70% 15.80% 16.41% 8.74% 10.28% 4.22% 5.35% 19.96% 16.55% 17.64% 20.58% PAT Growth 0.22% 5.70% 159.58% -13.11% 250.93% 7.62% -83.84% 6.53% 20.79% 40.37% EPS 2.64 2.58 2.44 0.94 1.08 0.31 0.29 1.77 1.67 1.38 0.98

Description TTM Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Net Sales 1,784.20 1,490.84 1,376.18 1,134.21 1,000.07 912.69 767.16 893.33 796.69 630.00 438.42 Net Sales Growth 27.17% 8.33% 21.33% 13.41% 9.57% 18.97% -14.12% 12.13% 26.46% 43.70% Cost Of Goods Sold 889.12 716.81 595.05 567.83 498.01 523.13 458.74 509.69 445.44 367.93 252.86 Gross Profit 895.08 774.02 781.13 566.38 502.07 389.57 308.42 383.63 351.25 262.07 185.56 GP Margin 50.17% 51.92% 56.76% 49.94% 50.20% 42.68% 40.20% 42.94% 44.09% 41.60% 42.32% Total Expenditure 1,490.80 1,231.96 1,036.58 941.96 867.92 834.31 734.24 760.91 620.86 516.04 369.02 Power & Fuel Cost - 18.59 16.42 14.38 14.34 11.83 13.27 12.58 9.72 7.80 6.12 % Of Sales - 1.25% 1.19% 1.27% 1.43% 1.30% 1.73% 1.41% 1.22% 1.24% 1.40% Employee Cost - 220.30 197.32 168.42 159.07 147.75 149.70 122.42 72.61 66.44 55.91 % Of Sales - 14.78% 14.34% 14.85% 15.91% 16.19% 19.51% 13.70% 9.11% 10.55% 12.75% Manufacturing Exp. - 192.77 127.47 113.32 77.14 59.90 47.34 50.44 37.59 30.11 9.85 % Of Sales - 12.93% 9.26% 9.99% 7.71% 6.56% 6.17% 5.65% 4.72% 4.78% 2.25% General & Admin Exp. - 47.41 50.67 45.52 51.03 42.51 37.52 36.01 15.35 16.13 24.93 % Of Sales - 3.18% 3.68% 4.01% 5.10% 4.66% 4.89% 4.03% 1.93% 2.56% 5.69% Selling & Distn. Exp. - 31.89 33.54 32.15 68.36 49.14 27.66 29.77 34.47 27.63 22.84 % Of Sales - 2.14% 2.44% 2.83% 6.84% 5.38% 3.61% 3.33% 4.33% 4.39% 5.21% Miscellaneous Exp. - 4.17 16.10 0.34 -0.01 0.05 0.00 0.00 5.67 0.00 22.84 % Of Sales - 0.28% 1.17% 0.03% 0.00% 0.01% 0% 0% 0.71% 0% -0.80% EBITDA 293.41 258.88 339.60 192.25 132.15 78.38 32.92 132.42 175.83 113.96 69.40 EBITDA Margin 16.44% 17.36% 24.68% 16.95% 13.21% 8.59% 4.29% 14.82% 22.07% 18.09% 15.83% Other Income 63.64 41.85 6.69 0.33 4.62 8.47 18.85 12.72 12.23 7.28 4.40 Interest 11.72 8.45 7.99 8.75 9.66 10.22 6.78 10.16 16.05 19.13 14.60 Depreciation 59.27 44.78 36.15 26.66 22.80 26.84 30.09 28.13 16.13 15.69 15.65 PBT 286.08 247.51 302.16 157.17 104.31 49.80 14.90 106.85 155.88 86.41 43.55 Tax 73.82 60.70 63.63 36.42 23.87 14.00 3.56 24.11 43.92 12.79 -5.28 Tax Rate 25.80% 24.52% 21.06% 23.17% 22.88% 28.11% 23.89% 22.56% 28.18% 14.80% -12.12% PAT 212.26 184.56 235.94 117.02 76.46 32.94 8.83 78.51 109.39 71.90 45.89 PAT before Minority Interest 214.02 186.81 238.54 120.75 80.44 35.80 11.33 82.74 111.96 73.62 48.83 Minority Interest 1.76 -2.25 -2.60 -3.73 -3.98 -2.86 -2.50 -4.23 -2.57 -1.72 -2.94 PAT Margin 11.90% 12.38% 17.14% 10.32% 7.65% 3.61% 1.15% 8.79% 13.73% 11.41% 10.47% PAT Growth -10.31% -21.78% 101.62% 53.05% 132.12% 273.05% -88.75% -28.23% 52.14% 56.68% EPS 5.27 4.58 5.85 2.90 1.90 0.82 0.22 1.95 2.71 1.78 1.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Shareholder's Funds 784.67 599.72 505.63 470.57 428.97 418.88 422.70 358.18 159.92 109.98 Share Capital 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 52.03 52.03 Total Reserves 650.64 558.79 464.69 429.64 388.04 377.95 369.27 304.75 107.89 57.95 Non-Current Liabilities 14.41 23.93 24.79 18.39 17.09 17.30 0.31 0.50 21.68 10.10 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.82 7.88 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 0.00 0.00 Current Liabilities 190.39 137.26 79.73 133.39 111.22 109.59 111.19 168.43 194.83 190.17 Trade Payables 74.45 64.16 56.65 37.23 33.68 20.60 31.41 44.58 40.50 29.86 Other Current Liabilities 78.95 42.70 10.92 7.34 8.79 0.71 0.68 39.88 73.59 75.05 Short Term Borrowings 5.00 0.00 0.00 77.33 66.31 73.23 40.62 43.52 58.06 75.31 Short Term Provisions 31.99 30.40 12.15 11.50 2.45 15.04 38.49 40.45 22.68 9.95 Total Liabilities 989.47 760.91 610.15 622.35 557.28 545.77 534.20 527.11 376.43 310.25 Net Block 135.51 129.09 115.18 102.61 87.89 93.92 97.47 90.01 66.82 72.85 Gross Block 301.34 277.25 248.77 224.90 201.83 195.61 184.48 162.47 130.24 127.62 Accumulated Depreciation 165.83 148.16 133.59 122.28 113.94 101.69 87.01 72.45 63.42 54.77 Non Current Assets 375.75 369.32 355.73 339.98 324.78 329.16 330.16 158.45 135.93 141.67 Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 0.00 Non Current Investment 236.07 236.07 236.07 236.07 236.07 234.29 231.44 67.62 67.62 67.62 Long Term Loans & Adv. 4.16 4.16 4.47 1.29 0.82 0.59 1.25 0.83 1.50 1.20 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 613.73 391.60 254.41 282.37 232.51 216.61 204.04 368.66 240.50 168.57 Current Investments 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 103.67 93.69 74.60 70.36 42.29 29.24 43.74 51.03 55.61 51.32 Sundry Debtors 246.78 168.93 161.87 177.83 168.87 154.80 133.41 124.63 112.38 91.42 Cash & Bank 224.05 105.61 3.35 1.80 0.71 2.56 3.13 167.54 33.37 0.41 Other Current Assets 38.78 1.91 0.82 7.47 20.62 30.01 23.76 25.46 39.14 25.43 Short Term Loans & Adv. 26.21 21.20 13.76 24.91 14.54 29.92 23.76 25.46 39.14 25.43 Net Current Assets 423.34 254.34 174.68 148.98 121.28 107.02 92.85 200.23 45.67 -21.60 Total Assets 989.48 760.92 610.14 622.35 557.29 545.77 534.20 527.11 376.43 310.24

Description Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Shareholder's Funds 1,202.27 886.50 636.01 542.48 470.86 433.43 454.32 379.76 142.18 86.48 Share Capital 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 52.03 52.03 Total Reserves 1,068.24 845.56 595.08 501.55 429.93 392.50 400.89 326.33 90.15 34.45 Non-Current Liabilities 57.05 23.70 24.15 17.14 15.64 16.07 -1.91 1.46 22.16 10.49 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.82 7.88 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 0.00 0.00 Current Liabilities 356.22 298.97 228.75 232.62 234.68 296.06 259.43 286.24 319.12 297.28 Trade Payables 200.08 168.66 110.33 106.07 77.83 161.78 118.98 107.02 83.18 56.06 Other Current Liabilities 96.80 79.69 58.86 20.90 10.08 0.71 0.68 39.88 96.58 108.73 Short Term Borrowings 41.29 18.74 18.84 99.91 117.41 109.71 87.89 82.19 105.54 113.79 Short Term Provisions 18.05 31.88 40.72 5.74 29.36 23.85 51.88 57.15 33.82 18.70 Total Liabilities 1,636.24 1,228.03 902.02 802.46 730.73 751.81 720.20 675.56 490.10 401.24 Net Block 428.31 309.36 302.72 269.73 279.38 266.98 269.65 165.90 145.65 156.12 Gross Block 726.26 551.92 565.39 506.26 495.35 456.49 429.47 297.78 261.70 256.88 Accumulated Depreciation 297.96 242.56 262.67 236.54 215.97 189.52 159.82 131.89 116.05 100.76 Non Current Assets 435.04 325.20 308.45 271.02 280.19 267.92 280.06 166.72 147.15 157.32 Capital Work in Progress 2.57 11.68 0.00 0.00 0.00 0.36 0.00 0.00 0.00 0.00 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 4.16 4.16 5.73 1.29 0.82 0.59 10.41 0.83 1.50 1.20 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 1,201.20 902.82 593.59 531.44 450.54 483.88 440.15 508.83 342.95 243.93 Current Investments 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 424.44 404.32 241.84 293.25 218.12 190.09 167.79 130.11 102.59 77.69 Sundry Debtors 394.78 271.95 243.35 176.60 176.91 247.58 217.29 183.45 169.61 131.31 Cash & Bank 349.26 212.18 93.73 33.54 39.88 25.16 35.30 185.27 46.95 15.88 Other Current Assets 32.29 14.11 11.26 28.06 15.63 21.05 19.76 10.01 23.80 19.04 Short Term Loans & Adv. 3.06 0.00 3.40 0.00 0.00 20.96 19.76 10.01 23.80 19.04 Net Current Assets 844.98 603.85 364.83 298.82 215.86 187.82 180.71 222.60 23.83 -53.36 Total Assets 1,636.24 1,228.02 902.04 802.46 730.73 751.80 720.21 675.55 490.10 401.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Cash From Operating Activity 50.97 106.92 107.58 19.81 15.63 -13.62 64.76 112.03 54.18 8.58 PBT 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 63.26 29.61 Adjustment -7.93 -8.82 19.17 11.57 20.00 12.50 8.82 17.75 14.87 15.35 Changes in Working Capital -43.77 11.62 46.17 -34.91 -16.33 -22.39 -15.35 28.53 -15.89 -35.98 Cash after chg. in Working capital 82.80 127.13 118.06 32.67 20.32 2.06 85.09 142.97 62.24 8.97 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -31.83 -20.21 -10.49 -12.86 -4.68 -15.69 -20.33 -30.94 -8.06 -0.39 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -8.39 8.87 -24.15 -20.20 -7.55 -7.69 -177.34 -29.14 -2.01 -48.24 Net Fixed Assets -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 -2.62 -4.85 Net Investments -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 0.00 -44.11 Others 15.88 37.61 -0.28 2.87 0.09 6.65 8.49 3.09 0.61 0.72 Cash from Financing Activity 75.86 -13.53 -81.87 0.96 -9.98 20.74 -51.83 51.28 -19.21 22.49 Net Cash Inflow / Outflow 118.44 102.26 1.55 0.56 -1.90 -0.57 -164.41 134.17 32.96 -17.17 Opening Cash & Equivalents 105.61 3.35 1.80 0.55 2.45 3.13 167.54 33.37 0.41 17.58 Closing Cash & Equivalent 224.05 105.61 3.35 1.12 0.55 2.56 3.13 167.54 33.37 0.41

Description Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Cash From Operating Activity 99.26 178.59 233.33 27.40 50.09 14.06 30.80 154.51 64.84 38.56 PBT 247.51 302.16 157.17 104.31 49.80 14.90 106.85 109.40 71.91 45.88 Adjustment 35.31 56.57 42.04 31.88 43.99 26.58 39.63 24.26 19.57 27.85 Changes in Working Capital -110.70 -131.61 59.12 -81.79 -36.23 -6.04 -88.14 20.27 -26.01 -35.18 Cash after chg. in Working capital 172.12 227.12 258.33 54.40 57.56 35.44 58.34 153.94 65.47 38.56 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -72.86 -48.53 -25.00 -27.00 -7.46 -21.37 -27.54 -0.89 -0.27 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -41.69 -44.85 -59.58 -13.48 -38.81 -20.73 -123.01 -33.19 -4.49 -5.43 Net Fixed Assets -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 -2.62 -4.85 Net Investments -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 0.00 -44.11 Others -17.42 -16.11 -35.71 9.59 -31.17 -6.39 62.82 -0.96 -1.87 43.53 Cash from Financing Activity 79.51 -15.29 -113.55 -20.78 3.38 -3.47 -57.75 16.99 -29.28 -39.64 Net Cash Inflow / Outflow 137.08 118.46 60.19 -6.86 14.67 -10.14 -149.96 138.32 31.07 -6.51 Opening Cash & Equivalents 212.18 93.73 33.54 39.72 25.05 35.30 185.27 46.95 15.88 22.39 Closing Cash & Equivalent 349.26 212.18 93.73 32.85 39.72 25.16 35.30 185.27 46.95 15.88

Financial Ratios

Consolidated /

Standalone

Description Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Book Value (Rs.) 16.90 14.65 12.35 11.50 10.48 10.23 10.02 8.45 3.80 2.50 ROA 11.88% 14.35% 6.15% 7.40% 2.25% 2.14% 13.47% 14.85% 16.18% 14.32% ROE 16.11% 17.80% 7.77% 9.70% 2.93% 2.79% 18.91% 27.27% 45.75% 0.00% ROCE 19.91% 23.46% 11.39% 11.99% 4.92% 3.44% 22.45% 33.41% 34.89% 70.55% Fixed Asset Turnover 2.30 2.30 1.83 1.99 1.48 1.14 2.06 2.77 2.44 1.54 Receivable days 114.03 99.91 143.04 149.17 200.47 243.69 131.50 106.64 118.09 157.17 Inventory Days 54.14 50.83 61.04 48.47 44.31 61.71 48.29 47.98 61.96 86.90 Payable days 66.99 65.25 47.33 37.28 36.94 45.72 53.08 52.33 53.91 79.75 Cash Conversion Cycle 101.18 85.49 156.75 160.37 207.84 259.68 126.70 102.30 126.15 164.32 Total Debt/Equity 0.01 0.00 0.00 0.17 0.16 0.17 0.10 0.14 0.56 0.82 Interest Cover 36.44 24.26 8.23 9.54 3.17 3.66 15.77 8.37 5.16 3.92

Description Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13
Book Value (Rs.) 27.10 21.66 15.54 13.25 11.50 10.59 10.79 8.97 3.34 1.89 ROA 13.04% 22.40% 14.17% 10.49% 4.83% 1.54% 11.86% 19.21% 16.52% 12.42% ROE 18.72% 31.33% 20.49% 15.88% 7.92% 2.59% 20.45% 45.15% 73.02% 0.00% ROCE 23.82% 39.76% 25.57% 18.51% 10.60% 3.99% 23.16% 44.64% 38.30% 44.72% Fixed Asset Turnover 2.42 2.49 2.12 2.00 1.92 1.73 2.46 2.85 2.43 1.73 Receivable days 78.56 67.57 67.57 64.51 84.88 110.59 81.87 80.88 87.17 101.60 Inventory Days 97.65 84.73 86.10 93.32 81.63 85.14 60.86 53.30 52.22 62.88 Payable days 93.88 85.57 45.09 38.48 55.10 65.56 54.58 56.06 48.85 59.34 Cash Conversion Cycle 82.33 66.73 108.58 119.35 111.40 130.17 88.15 78.13 90.54 105.14 Total Debt/Equity 0.04 0.02 0.03 0.18 0.25 0.25 0.19 0.23 1.12 1.88 Interest Cover 30.31 38.84 18.97 11.80 5.87 3.20 11.52 10.72 5.52 3.98

Top Investors:

investor education and protection fund (iepf)

Annual Reports:

News Update:

Marksans Pharma gets USFDA’s final approval for Famotidine Tablets
10th Mar 2023, 12:21 PM

The product is bioequivalent to the reference listed drug, Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer
Read More
Marksans Pharma - Quarterly Results
13th Feb 2023, 13:40 PM

Read More
Marksans Pharma’s arm gets UK MHRA approval for Fluoxetine Oral Solution
23rd Jan 2023, 14:27 PM

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders
Read More
Marksans Pharma raises Rs 372.40 crore via conversion of warrants
20th Jan 2023, 16:46 PM

OrbiMed's exercise of warrant conversion will further strengthen the Company's net cash position to over Rs 650 crore
Read More

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: